How to pay for individualized genetic medicines

doi:10.1038/s41591-024-03071-x

. 2024 Jul;30(7):1816-1818.

doi: 10.1038/s41591-024-03071-x.

How to pay for individualized genetic medicines

Julia M Y Pian^#^{1

2}, Nana Owusu^#³, Julia Vitarello^{4

5}, Winston X Yan⁴, Andrew W Lo^{6

7}, Timothy W Yu^{8

9

10}

Affiliations

¹ Boston Children's Hospital, Boston, MA, USA. julia.pian@childrens.harvard.edu.
² N=1 Collaborative, Boston, MA, USA. julia.pian@childrens.harvard.edu.
³ Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
⁴ N=1 Collaborative, Boston, MA, USA.
⁵ Mila's Miracle Foundation, Boulder, CO, USA.
⁶ MIT Sloan School of Management, MIT Laboratory for Financial Engineering, MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.
⁷ Santa Fe Institute, Santa Fe, NM, USA.
⁸ Boston Children's Hospital, Boston, MA, USA. timothy.yu@childrens.harvard.edu.
⁹ N=1 Collaborative, Boston, MA, USA. timothy.yu@childrens.harvard.edu.
¹⁰ Harvard Medical School, Boston, MA, USA. timothy.yu@childrens.harvard.edu.

^# Contributed equally.

PMID: 38898122
DOI: 10.1038/s41591-024-03071-x

How to pay for individualized genetic medicines

Julia M Y Pian et al. Nat Med. 2024 Jul.

. 2024 Jul;30(7):1816-1818.

doi: 10.1038/s41591-024-03071-x.

Authors

Julia M Y Pian^#^{1

2}, Nana Owusu^#³, Julia Vitarello^{4

5}, Winston X Yan⁴, Andrew W Lo^{6

7}, Timothy W Yu^{8

9

10}

Affiliations

¹ Boston Children's Hospital, Boston, MA, USA. julia.pian@childrens.harvard.edu.
² N=1 Collaborative, Boston, MA, USA. julia.pian@childrens.harvard.edu.
³ Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA.
⁴ N=1 Collaborative, Boston, MA, USA.
⁵ Mila's Miracle Foundation, Boulder, CO, USA.
⁶ MIT Sloan School of Management, MIT Laboratory for Financial Engineering, MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.
⁷ Santa Fe Institute, Santa Fe, NM, USA.
⁸ Boston Children's Hospital, Boston, MA, USA. timothy.yu@childrens.harvard.edu.
⁹ N=1 Collaborative, Boston, MA, USA. timothy.yu@childrens.harvard.edu.
¹⁰ Harvard Medical School, Boston, MA, USA. timothy.yu@childrens.harvard.edu.

^# Contributed equally.

PMID: 38898122
DOI: 10.1038/s41591-024-03071-x

No abstract available

PubMed Disclaimer

Cited by

Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design.
Bou-Jaoudeh M, Piaton-Breda G, Pereme F, Gilbert S. Bou-Jaoudeh M, et al. Ther Innov Regul Sci. 2025 May;59(3):505-518. doi: 10.1007/s43441-025-00752-8. Epub 2025 Feb 27. Ther Innov Regul Sci. 2025. PMID: 40014258 Free PMC article. Review.
From roadmap to a sustainable end-to-end individualized therapy pathway.
Jonker AH, Tataru EA, Dimmock DP, Bateman-House A, Graessner H, Baynam G, Augustine EF, Jaffe A, Pasmooij AMG, Iliach O, Horgan R, Davies J, Mitkus S, Lapteva L, Synofzik M, Yu TW, O'Connor D, Aartsma-Rus A. Jonker AH, et al. Ther Adv Rare Dis. 2025 May 27;6:26330040251339204. doi: 10.1177/26330040251339204. eCollection 2025 Jan-Dec. Ther Adv Rare Dis. 2025. PMID: 40438698 Free PMC article. Review.
A father's crusade in rare disease drug development: a case study of Elpida therapeutics and Melpida.
Portero D, Xu Q, Hussain A, Lo AW. Portero D, et al. Orphanet J Rare Dis. 2025 Jul 16;20(1):363. doi: 10.1186/s13023-025-03892-0. Orphanet J Rare Dis. 2025. PMID: 40665386 Free PMC article.
A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases.
Kim-McManus O, Gleeson JG, Mignon L, Smith Fine A, Yan W, Nolen N, Demarest S, Berry-Kravis E, Finkel R, Leonard S, Finlayson S, Augustine E, Lyon GJ, Schule R, Yu T. Kim-McManus O, et al. Nat Commun. 2024 Nov 12;15(1):9802. doi: 10.1038/s41467-024-54077-5. Nat Commun. 2024. PMID: 39532857 Free PMC article. Review.
The impact of rare diseases on the quality of life in paediatric patients: current status.
Dumbuya JS, Zeng C, Deng L, Li Y, Chen X, Ahmad B, Lu J. Dumbuya JS, et al. Front Public Health. 2025 Mar 24;13:1531583. doi: 10.3389/fpubh.2025.1531583. eCollection 2025. Front Public Health. 2025. PMID: 40196857 Free PMC article. Review.

See all "Cited by" articles

References

1. Kim, J. et al. N. Engl. J. Med. 381, 1644–1652 (2019). - DOI - PubMed - PMC
1. Korobeynikov, V. A. et al. Nat. Med. 28, 104–116 (2022). - DOI - PubMed - PMC
1. Tran, H. et al. Nat. Med. 28, 117–124 (2022). - DOI - PubMed
1. Kim, J. et al. Nature 619, 828–836 (2022). - DOI
1. US Food & Drug Administration. Draft Guidance for Industry https://go.nature.com/3RimwVu (December 2021).

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

[1] Kim, J. et al. N. Engl. J. Med. 381, 1644–1652 (2019). - DOI - PubMed - PMC

[2] Kim, J. et al. N. Engl. J. Med. 381, 1644–1652 (2019). - DOI - PubMed - PMC

[3] Korobeynikov, V. A. et al. Nat. Med. 28, 104–116 (2022). - DOI - PubMed - PMC

[4] Korobeynikov, V. A. et al. Nat. Med. 28, 104–116 (2022). - DOI - PubMed - PMC

[5] Tran, H. et al. Nat. Med. 28, 117–124 (2022). - DOI - PubMed

[6] Tran, H. et al. Nat. Med. 28, 117–124 (2022). - DOI - PubMed

[7] Kim, J. et al. Nature 619, 828–836 (2022). - DOI

[8] Kim, J. et al. Nature 619, 828–836 (2022). - DOI

[9] US Food & Drug Administration. Draft Guidance for Industry https://go.nature.com/3RimwVu (December 2021).

[10] US Food & Drug Administration. Draft Guidance for Industry https://go.nature.com/3RimwVu (December 2021).

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

How to pay for individualized genetic medicines

Affiliations

How to pay for individualized genetic medicines

Authors

Affiliations

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources